Roche announces positive preliminary results from the Phase II KARDIA-2 study in hypertension, with clinically significant reductions in systolic blood pressure at three months with zilebesiran, when added to standard therapy.

The KARDIA-2 study not only met its primary endpoint, but also demonstrated an encouraging safety and tolerability profile for zilebesiran in adults with mild-to-moderate uncontrolled hypertension.

The results of the study will be presented in April at the annual meeting of the American College of Cardiology. Another Phase II study, KARDIA-3, has also been initiated in adults with uncontrolled hypertension at high cardiovascular risk.

Copyright (c) 2024 CercleFinance.com. All rights reserved.